B7-H5, a costimulatory polypeptide

Patent metadata

Field	Value
Publication number	US-11760787-B2
Application number	US-201916707719-A
Country	US
Kind code	B2
Filing date	Dec 9, 2019
Priority date	Jun 24, 2004
Publication date	Sep 19, 2023
Grant date	Sep 19, 2023

Abstract

B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.

First claim

What I claim is:

1. A method of suppressing T cell immunity in a subject, said method comprising administering to the subject a composition comprising a fusion protein and a pharmaceutically acceptable carrier, wherein said fusion protein comprises:
a first domain that consists of an amino acid sequence encoded by a nucleic acid sequence that encodes a protein consisting of an extracellular region of a protein, wherein the nucleic acid sequence hybridizes over its full length, after a wash at 50° C. to 60° C. in a buffer containing 0.2× SSC and 0.1% SDS, to the complement of a nucleotide sequence consisting of nucleotide 88 to nucleotide 936 of SEQ ID NO:2; and
at least one additional domain comprising an amino acid sequence that is unrelated to SEQ ID NO:1.

2. The method of claim 1 , wherein said at least one additional domain is all or part of an immunoglobulin heavy chain constant region.

3. The method of claim 1 , wherein said fusion protein comprises amino acid 40 to amino acid 190 of SEQ ID NO:1.

4. The method of claim 1 , wherein said fusion protein comprises amino acid 35 to amino acid 190 of SEQ ID NO:1.

5. The method of claim 1 , wherein said fusion protein comprises amino acid 30 to amino acid 190 of SEQ ID NO:1.

6. The method of claim 1 , wherein said nucleic acid sequence hybridizes over its full length, after a wash at 50° C. to 60° C. in a buffer containing 0.2× SSC and 0.1% SDS, to the complement of a nucleotide sequence consisting of nucleotide 88 to nucleotide 570 of SEQ ID NO:2.

7. The method of claim 1 , wherein said pharmaceutically acceptable carrier is physiological saline.

8. A method of suppressing T cell immunity in a subject, said method comprising administering to the subject a composition comprising a fusion protein and a pharmaceutically acceptable carrier, wherein said fusion protein comprises:
a first domain consisting of a polypeptide that consists of all or part of amino acid 30 to amino acid 311 of SEQ ID NO:1 and includes at least an V-like Ig domain consisting of amino acid 47 to amino acid 150 of SEQ ID NO:1; and
at least one additional domain comprising an amino acid sequence that is unrelated to SEQ ID NO:1.

9. The method of claim 8 , wherein said at least one additional domain is all or part of an immunoglobulin heavy chain constant region.

10. The method of claim 8 , wherein said fusion protein comprises amino acid 40 to amino acid 311 of SEQ ID NO: 1.

11. The method of claim 8 , wherein said fusion protein comprises amino acid 35 to amino acid 311 of SEQ ID NO:1.

12. The method of claim 8 , wherein said fusion protein comprises amino acid 30 to amino acid 311 of SEQ ID NO:1.

13. The method of claim 8 , wherein said pharmaceutically acceptable carrier is physiological saline.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Chen Lieping

Classifications

• C07K14/70532 Primary

  B7 molecules, e.g. CD80, CD86 · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• C07K16/46

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title